Riassunto
Le terapie mediche proponibili nei tumori neuroendocrini (NET) sono diverse e non esiste una prima linea o una sequenza definibile “standard”. Nei NET ben differenziati analoghi della somatostatina, interferone, farmaci a bersaglio molecolare e chemioterapia sono tutte opzioni terapeutiche proponibili e vanno adattate al singolo paziente. Abbiamo finalmente evidenza di primo livello che l’octreotide long-acting release prolunghi il tempo libero da progressione (PFS: progression free survival) nei NET del piccolo intestino “naive” anche non funzionanti e che l’everolimus e il sunitinib prolunghino il PFS nei NET pancreatici radiologicamente progressivi. Nessuno studio di fase III ha finora dimostrato un vantaggio statisticamente significativo sulla sopravvivenza globale.
This is a preview of subscription content, log in via an institution to check access.
Bibliografia
Yao JC, Hassan M, Phan A, et al 2008 One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072.
Pape UF, Berndt U, Müller-Nordhorn J, et al 2008 Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15:10–83–97.
Ekeblad S, Skogseid B, Dunder C, Oberg K, Eriksson B 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14:7798–7803.
Bosman TF, Carneiro F, Hruban RH, Theise ND eds 2010 WHO Classification of Tumours of the Digestive System, 4th ed. Lyon: International Agency for Research on Cancer (IARC), 13–14.
Mitry E, Rougier P 2001 The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol 37:47–51.
Yao JC, Shah MH, Ito T, et al 2011 Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523.
Raymond E, Dahan L, Raoul JL, et al 2011 Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513.
Protocol IDs: CSOM230I2201, NCT01374451.
Protocol IDs: A6181202, NCT01525550.
Rinke A, Müller HH, Schade-Brittinger C, et al 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27:4656–4663.
Pavel M, Hainsworth JD, Baudin E et al 2011 Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012.
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A 2010 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. J Nucl Med 51:704–712.
Koopmans KP, Neels ON, Kema IP, et al 2009 Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. Crit Rev Hem Oncol 71:199–213.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fazio, N., Spada, F. La terapia medica dei tumori neuroendocrini. L’Endocrinologo 13, 158–162 (2012). https://doi.org/10.1007/BF03345979
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345979